Mereo BioPharma GroupMREO +3.62%19 PB Ratio is 1.57 as of Jul. 04, 2026, which is 74% below its 10-year median of 6.08. GuruFocus rates MREO with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 1,228 Biotechnology companies, Mereo BioPharma Group ranks better than 71.09% on this metric.
The historical rank and industry rank for Mereo BioPharma Group's PB Ratio or its related term are showing as below:
MREO'
s PB Ratio Range Over the Past 10 Years
Min: 1.13 Med: 6.08 Max: 14.03
Current: 1.53
During the past 11 years, Mereo BioPharma Group's highest PB Ratio was 14.03. The lowest was 1.13. And the median was 6.08.
MREO's PB Ratio is ranked better than 71.09% of 1228
companies
in the Biotechnology industry
Industry Median: 2.97
vs MREO: 1.53
During the past 12 months, Mereo BioPharma Group's average Book Value Per Share Growth Rate was -43.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -14.60% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Mereo BioPharma Group was -7.80% per year. The lowest was -46.50% per year. And the median was -28.40% per year.
Back to Basics: PB Ratio
Mereo BioPharma Group (NAS:MREO) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Mereo BioPharma Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mereo BioPharma Group PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where Mereo BioPharma Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Mereo BioPharma Group (MREO) has a PB Ratio of 1.57 as of Jul. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Mereo BioPharma Group and its competitors. This is 74% below median its historical median of 6.08. Over the past decade, Mereo BioPharma Group's PB Ratio has ranged from 1.13 to 14.03. According to the industry distribution chart, Mereo BioPharma Group ranks #355 out of 1228 companies in the Biotechnology industry, placing it in the top 28.9%.
Is Mereo BioPharma Group's PB Ratio too high?
Mereo BioPharma Group's current PB Ratio of 1.57 is 74% below median its 10-year median of 6.08. Over the past 10 years, this metric has ranged from a low of 1.13 to a high of 14.03. The Biotechnology industry median PB Ratio is 2.97. Mereo BioPharma Group's value of 1.57 is 47.1% below this industry median. Based on the distribution chart, Mereo BioPharma Group ranks #355 out of 1228 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Mereo BioPharma Group has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Mereo BioPharma Group's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mereo BioPharma Group ranks #355 out of 1228 companies for PB Ratio. This puts Mereo BioPharma Group in the upper half of its industry. The industry median PB Ratio is 2.97. Mereo BioPharma Group's value of 1.57 is 47.1% below this benchmark. Historically, Mereo BioPharma Group's own PB Ratio has ranged from 1.13 to 14.03 over the past decade. While the company's 10-year median is 6.08 vs. the industry median of 2.97, Mereo BioPharma Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.97, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mereo BioPharma Group's current PB Ratio of 1.57 is 47.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Mereo BioPharma Group and its competitors. For the Biotechnology industry, the median PB Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mereo BioPharma Group's current PB Ratio is 1.57, which is 74% below median its own 10-year median of 6.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mereo BioPharma Group stock overvalued right now?
Mereo BioPharma Group (MREO) has a current PB Ratio of 1.57. The current PB Ratio is 1.57, which is 74% below median its 10-year median of 6.08 and 47.1% below the Biotechnology industry median of 2.97. Mereo BioPharma Group's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Mereo BioPharma Group (MREO), the current PB Ratio is 1.57 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
19GF Score
Get the complete analysis for MREO
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MREO has been successfully added to your 
